Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Obinutuzumab +/- Radiotherapy in Treatment-Naive Follicular Lymphoma
NCT04962126Phase 2Active, not recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and obinutuzumab in follicular lymphoma (FL), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Complete Metabolic Response Rate. Started Aug 2021; status: active, not recruiting.
02
Drugs
atezolizumabobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04962126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962126.